Leap Therapeutics, Inc. (LPTX)

3.2500 +0.0800 (+2.52%) At close: 04:00PM EDT

Leap Therapeutics, Inc.

47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
United States
617 714 0360
https://www.leaptx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 54

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Douglas E. Onsi J.D.	CFO, General Counsel, Treasurer & Secretary, President, CEO & Director	1.04M	N/A	1969
Mr. Augustine J. Lawlor	Chief Operating Officer	713.57k	N/A	1957
Dr. Cynthia A. Sirard	Chief Medical Officer	708.64k	N/A	1970
Dr. Jason S. Baum Ph.D.	Chief Scientific Officer	N/A	N/A	1979
Mr. Mark O'Mahony	Chief Manufacturing Officer	N/A	N/A	1971
Ms. Christine M. Granfield	VP and Head of Regulatory Affairs & Quality	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Corporate governance

Leap Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.